Clinical Data

Cartoon of businessmen standing around a broken target

Spine BioPharma misses primary endpoint in back pain phase 3

With the biotech pinning the flop on a “very high sham control response,” management plans to meet with the FDA to discuss a potential path to market.

Nick Paul Taylor Aug 1, 2025 10:24am

4DMT climbs as gene therapy patients keep jettisoning jabs

Aug 1, 2025 5:35am

graphic image of China flags overlapping with US flags

Instil's licensed PD-L1xVEGF bispecific shows promise in China

Jul 31, 2025 2:10pm

Nuvectis axes ovarian cancer program after seeing phase 1b data

Jul 31, 2025 9:15am

Vyne's BET inhibitor fails phase 2 vitiligo trial, sinking stock

Jul 30, 2025 9:35am

Multiple screens displaying stock tickers and financial information

Cardiff posts updated colorectal cancer data, sinking stock

Jul 30, 2025 7:25am